Atovaquone for PJP Prophylaxis

Indications and Patient Selection

• The European League Against Rheumatism and National Comprehensive Cancer Network recommend atovaquone 1500 mg daily as a first-line alternative when TMP-SMX is not tolerated 1, 2
• All alternative agents, including atovaquone, are less effective than TMP-SMX, which remains the gold standard 1

Dosing and Administration

• Food increases atovaquone bioavailability 1.4-fold compared to fasting state; failure to take with food may result in subtherapeutic levels and prophylaxis failure 3

Comparison to Other Alternatives

• Dapsone 100 mg daily is the most well-established alternative per the National Comprehensive Cancer Network, but requires G6PD testing and monitoring for methemoglobinemia 1
• Aerosolized pentamidine 300 mg monthly via Respirgard II nebulizer is effective but requires monthly healthcare visits 1
• Atovaquone 1500 mg daily offers the convenience of oral daily dosing without the hematologic monitoring required for dapsone 1

Duration of Prophylaxis

• Continue prophylaxis for the duration of immunosuppression 2
• For HIV patients: until CD4+ count >200 cells/μL for at least 3 months 1
• For transplant recipients: at least 6-12 months post-transplantation 1, 2
• For patients on corticosteroids: while receiving ≥20 mg prednisone daily or equivalent 1, 2

Adverse Effects

• Common adverse reactions include skin rashes (10-15%), nausea, and diarrhea, typically occurring after the first week of therapy 3

Limitations

• Atovaquone does not provide the additional protection against common bacterial infections that TMP-SMX offers 1